Who are Desogestrel-Ethinyl Estradiol 21 tablets's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): norelgestromin + ethinyl estradiol, Drospirenone Ethinyl estradiol Myo-inositol, Female Contraceptive, YAZ®, Drospirenone / Estetrol, Intermittent OC (EE/DROS).

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/desogestrel-ethinyl-estradiol-21-tablets.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-17 · How we verify

Desogestrel-Ethinyl Estradiol 21 tablets — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Desogestrel-Ethinyl Estradiol 21 tablets (Desogestrel-Ethinyl Estradiol 21 tablets) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Oral contraceptive. Area: Contraception.

phase 3 Oral contraceptive Progesterone receptor, estrogen receptor Contraception Small molecule Live · refreshed every 30 min

Target snapshot

Desogestrel-Ethinyl Estradiol 21 tablets (Desogestrel-Ethinyl Estradiol 21 tablets) — The Hospital for Sick Children. Desogestrel-ethinyl estradiol prevents ovulation by suppressing the luteinizing hormone surge through progestin and estrogen feedback on the hypothalamic-pituitary axis.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
Desogestrel-Ethinyl Estradiol 21 tablets TARGET	Desogestrel-Ethinyl Estradiol 21 tablets	The Hospital for Sick Children	phase 3	Oral contraceptive	Progesterone receptor, estrogen receptor
norelgestromin + ethinyl estradiol	norelgestromin + ethinyl estradiol	Johnson & Johnson Pharmaceutical Research & Development, L.L.C.	marketed	Combined oral contraceptive (progestin + estrogen)	Progesterone receptor, estrogen receptor
Drospirenone Ethinyl estradiol Myo-inositol	Drospirenone Ethinyl estradiol Myo-inositol	AGUNCO Obstetrics and Gynecology Centre	marketed	Oral contraceptive with insulin sensitizer	Progesterone receptor, estrogen receptor, inositol signaling pathway
Female Contraceptive	Female Contraceptive	Italfarmaco	marketed	Hormonal contraceptive	Progesterone receptor, estrogen receptor
YAZ®	YAZ®	Teva Pharmaceuticals USA	marketed	Oral contraceptive (combined estrogen-progestin)	Progesterone receptor, estrogen receptor, mineralocorticoid receptor
Drospirenone / Estetrol	Drospirenone / Estetrol	University of Palermo	marketed	Combined oral contraceptive	Progesterone receptor, estrogen receptor
Intermittent OC (EE/DROS)	Intermittent OC (EE/DROS)	University of North Carolina, Chapel Hill	marketed	Oral contraceptive	Progesterone receptor, estrogen receptor

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Oral contraceptive class)

University of North Carolina, Chapel Hill · 2 drugs in this class
The Hospital for Sick Children · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Desogestrel-Ethinyl Estradiol 21 tablets — Competitive Intelligence Brief. https://druglandscape.com/ci/desogestrel-ethinyl-estradiol-21-tablets. Accessed 2026-05-17.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab